The intravitreal dexamethasone implant Ozurdex® (Allergan, Inc, Irvine, Calif.) is
indicated for the treatment of diabetic macular edema, venous occlusion of the retinal
vessels, and noninfectious uveitis. In phakic patients, it is suggested that the injection
should be done 4 mm posterior to the corneal limbus, directing the needle to the optic
nerve, preferably in the inferotemporal quadrant. Although it is a rare event, inadvertent
intracrystalline injection of the dexamethasone implant has been reported in the literature
and can lead to complications such as cataract, glaucoma, and visual impairment.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of OphthalmologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article Info
Publication History
Published online: October 04, 2021
Accepted:
August 11,
2021
Received:
August 4,
2021
Identification
Copyright
© 2021 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.
